{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T06:08:17Z","timestamp":1793513297927,"version":"4.5.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Maor Foundation"},{"DOI":"10.13039\/100018785","name":"Gastro-Intestinal Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018785","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10620-023-08178-8","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T17:02:21Z","timestamp":1702400541000},"page":"579-587","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center"],"prefix":"10.1007","volume":"69","author":[{"given":"Nathaniel A.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Picker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Krugliak Cleveland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushila R.","family":"Dalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Pekow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5647-1723","authenticated-orcid":false,"given":"David T.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"issue":"3","key":"8178_CR1","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/AJG.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114:384\u2013413. https:\/\/doi.org\/10.14309\/AJG.0000000000000152.","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"8178_CR2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.mcna.2007.12.002","volume":"92","author":"F Marrero","year":"2008","unstructured":"Marrero F, Qadeer MA, Lashner BA. Severe Complications of Inflammatory Bowel Disease. Med Clin North Am. 2008;92:671\u2013686. https:\/\/doi.org\/10.1016\/j.mcna.2007.12.002.","journal-title":"Med Clin North Am."},{"issue":"4","key":"8178_CR3","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","volume":"24","author":"SR Knowles","year":"2018","unstructured":"Knowles SR, Graff LA, Wilding H, Hewitt C, Keefer L, Mikocka-Walus A. Quality of Life in Inflammatory Bowel Disease: A Systematic Review and Meta-analyses - Part i. Inflamm Bowel Dis. 2018;24:742\u2013751. https:\/\/doi.org\/10.1093\/ibd\/izx100.","journal-title":"Inflamm Bowel Dis."},{"key":"8178_CR4","doi-asserted-by":"publisher","unstructured":"Singh S, George J, Boland BS, Casteele N Vande, Sandborn WJ. Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with Inflammatory bowel diseases: A systematic review and meta-analysis. J Crohn\u2019s Colitis. 2018;12:635\u2013643. doi:https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy004","DOI":"10.1093\/ecco-jcc\/jjy004"},{"issue":"5","key":"8178_CR5","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/J.AUTREV.2017.03.007","volume":"16","author":"L Peyrin-Biroulet","year":"2017","unstructured":"Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. Autoimmun Rev. 2017;16:495\u2013503. https:\/\/doi.org\/10.1016\/J.AUTREV.2017.03.007.","journal-title":"Autoimmun Rev."},{"issue":"8","key":"8178_CR6","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1194\/JLR.R046300","volume":"55","author":"VA Blaho","year":"2014","unstructured":"Blaho VA, Hla T. Thematic Review Series: Lysophospholipids and their Receptors: An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014;55:1596. https:\/\/doi.org\/10.1194\/JLR.R046300.","journal-title":"J Lipid Res."},{"issue":"14","key":"8178_CR7","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1056\/nejmoa2033617","volume":"385","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, D\u2019Haens G et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021;385:1280\u20131291. https:\/\/doi.org\/10.1056\/nejmoa2033617.","journal-title":"N Engl J Med."},{"key":"8178_CR8","doi-asserted-by":"publisher","unstructured":"Johnson C, Barnes EL, Zhang X, Long MD. Trends and characteristics of clinical trials participation for inflammatory bowel disease in the United States: A report from IBD partners. Crohn\u2019s Colitis 360. 2020;2(2). doi:https:\/\/doi.org\/10.1093\/crocol\/otaa023","DOI":"10.1093\/crocol\/otaa023"},{"key":"8178_CR9","doi-asserted-by":"publisher","unstructured":"Cohen NA, Choi D, Choden T, Cleveland NK, Cohen RD, Rubin DT. Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data from a Large Tertiary Center. Clin Gastroenterol Hepatol. 2022;0(0). doi:https:\/\/doi.org\/10.1016\/j.cgh.2022.03.035","DOI":"10.1016\/j.cgh.2022.03.035"},{"issue":"1","key":"8178_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/GUT.43.1.29","volume":"43","author":"RS Walmsley","year":"1998","unstructured":"Walmsley RS, Ayres RCS, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut. 1998;43:29\u201332. https:\/\/doi.org\/10.1136\/GUT.43.1.29.","journal-title":"Gut."},{"key":"8178_CR11","unstructured":"Sandborn W, D\u2019Haens G, Wolf D, et al. Ozanimod for Moderate-to-Severe Ulcerative Colitis: Efficacy, Safety, and Histology Results from the Induction and Maintenance Periods of the Phase 3 True North Study. UEG week 2020 - late Break absract. Published online 2020."},{"key":"8178_CR12","doi-asserted-by":"publisher","unstructured":"Kayal M, Ungaro RC, Bader G, Colombel JF, Sandborn WJ, Stalgis C. Net Remission Rates with Biologic Treatment in Crohn\u2019s Disease: A Reappraisal of the Clinical Trial Data. Clin Gastroenterol Hepatol. 2022;0(0). doi:https:\/\/doi.org\/10.1016\/j.cgh.2022.02.044","DOI":"10.1016\/j.cgh.2022.02.044"},{"key":"8178_CR13","doi-asserted-by":"crossref","unstructured":"Dignass A, Regueiro M, Colombel JF, et al. P687 Durability of recaptured response to ozanimod during the True North open-label extension. J Crohn\u2019s Colitis. 2023;17:i817-i818. Accessed April 10, 2023. https:\/\/academic.oup.com\/ecco-jcc\/article\/17\/Supplement_1\/i817\/7010146","DOI":"10.1093\/ecco-jcc\/jjac190.0817"},{"issue":"7","key":"8178_CR14","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","volume":"4","author":"V Brinkmann","year":"2004","unstructured":"Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant. 2004;4:1019\u20131025. https:\/\/doi.org\/10.1111\/j.1600-6143.2004.00476.x.","journal-title":"Am J Transplant."},{"issue":"5","key":"8178_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMOA0909494\/SUPPL_FILE\/NEJMOA0909494_DISCLOSURES.PDF","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue E-W, O\u2019Connor P et al. A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis. N Engl J Med. 2010;362:387\u2013401. https:\/\/doi.org\/10.1056\/NEJMOA0909494\/SUPPL_FILE\/NEJMOA0909494_DISCLOSURES.PDF.","journal-title":"N Engl J Med."},{"issue":"6","key":"8178_CR16","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","volume":"13","author":"PA Calabresi","year":"2014","unstructured":"Calabresi PA, Radue EW, Goodin D et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545\u2013556. https:\/\/doi.org\/10.1016\/S1474-4422(14)70049-3.","journal-title":"Lancet Neurol."},{"issue":"4","key":"8178_CR17","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2217\/CER-2019-0169\/SUPPL_FILE\/SUPPL_DATA.ZIP","volume":"9","author":"E Swallow","year":"2020","unstructured":"Swallow E, Patterson-Lomba O, Yin L et al. Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. J Comp Eff Res. 2020;9:275\u2013285. https:\/\/doi.org\/10.2217\/CER-2019-0169\/SUPPL_FILE\/SUPPL_DATA.ZIP.","journal-title":"J Comp Eff Res."},{"issue":"8","key":"8178_CR18","doi-asserted-by":"publisher","first-page":"e114","DOI":"10.1093\/IBD\/IZAC032","volume":"28","author":"DK Choi","year":"2022","unstructured":"Choi DK, Rubin DT, Puangampai A, Cleveland N. Hypertensive Emergency After Initiating Ozanimod: A Case Report. Inflamm Bowel Dis. 2022;28:e114\u2013e115. https:\/\/doi.org\/10.1093\/IBD\/IZAC032.","journal-title":"Inflamm Bowel Dis."},{"key":"8178_CR19","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.2147\/DDDT.S240861","volume":"15","author":"M Fronza","year":"2021","unstructured":"Fronza M, Lorefice L, Frau J, Cocco E. An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis. Drug Des Devel Ther. 2021;15:1993\u20132004. https:\/\/doi.org\/10.2147\/DDDT.S240861.","journal-title":"Drug Des Devel Ther."},{"issue":"12","key":"8178_CR20","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1007\/s12325-020-01500-0","volume":"37","author":"JQ Tran","year":"2020","unstructured":"Tran JQ, Zhang P, Walker S et al. Multiple-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites and the Pharmacodynamic and Pharmacokinetic Interactions with Pseudoephedrine, a Sympathomimetic Agent. Healthy Subjects. Adv Ther. 2020;37:4944\u20134958. https:\/\/doi.org\/10.1007\/s12325-020-01500-0.","journal-title":"Healthy Subjects. Adv Ther."},{"issue":"11","key":"8178_CR21","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMra041867","volume":"352","author":"EW Boyer","year":"2005","unstructured":"Boyer EW, Shannon M. Current concepts: The serotonin syndrome. N Engl J Med. 2005;352:1112\u20131120. https:\/\/doi.org\/10.1056\/NEJMra041867.","journal-title":"N Engl J Med."},{"issue":"3","key":"8178_CR22","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1097\/MIB.0000000000000620","volume":"22","author":"A Mikocka-Walus","year":"2015","unstructured":"Mikocka-Walus A, Knowles SR, Keefer L, Graff L. Controversies Revisited: A Systematic Review of the Comorbidity of Depression and Anxiety with Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2015;22:752\u2013762. https:\/\/doi.org\/10.1097\/MIB.0000000000000620.","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"8178_CR23","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/MIB.0000000000001059","volume":"23","author":"BJD Macer","year":"2017","unstructured":"Macer BJD, Prady SL, Mikocka-Walus A. Antidepressants in Inflammatory Bowel Disease: A Systematic Review. Inflamm Bowel Dis. 2017;23:534\u2013550. https:\/\/doi.org\/10.1097\/MIB.0000000000001059.","journal-title":"Inflamm Bowel Dis."},{"key":"8178_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102844","volume":"51","author":"KW Selmaj","year":"2021","unstructured":"Selmaj KW, Cohen JA, Comi G et al. Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. Mult Scler Relat Disord. 2021;51:102844. https:\/\/doi.org\/10.1016\/j.msard.2021.102844.","journal-title":"Mult Scler Relat Disord."},{"issue":"7","key":"8178_CR25","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/ecco-jcc\/jjab012","volume":"15","author":"WJ Sandborn","year":"2021","unstructured":"Sandborn WJ, Feagan BG, Hanauer S et al. Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results from the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study. J Crohn\u2019s Colitis. 2021;15:1120\u20131129. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab012.","journal-title":"J Crohn\u2019s Colitis."},{"key":"8178_CR26","unstructured":"Celgene Corporation. Zeposia. Package insert. Fda. Published online 2021. Accessed December 15, 2021. www.fda.gov\/medwatchU"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-023-08178-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-023-08178-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T18:19:16Z","timestamp":1707761956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-023-08178-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["8178"],"URL":"https:\/\/doi.org\/10.1007\/s10620-023-08178-8","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nathaniel A. Cohen has served as a consultant for Iterative Health, Takeda and Seres Pharmaceuticals and has received travel support from Pfizer. David T. Rubin has received grant support from Takeda; and has served as a consultant for Abbvie, Abgenomics, Arena Pharmaceuticals, Bellatrix Pharmaceuticals, Boehringer Ingelheim Ltd., Bristol-Myers Squibb, Celgene, Syneos, Dizal Pharmaceuticals, Genentech\/Roche, Gilead Sciences, Ichnos Sciences S.A., InDex Pharmaceuticals, Iterative Scopes, Janssen Pharmaceuticals, Lilly, Pfizer, Prometheus Laboratories, Reistone, Takeda, and Techlab Inc. Russell D. Cohen serves on the speakers\u2019 bureau for Abbvie, BMS, and Takeda, and has served as a consultant for Abbvie, BMS, Eli Lilly, Genentech, Gilead Sciences, Hoffman La-Roche, Janssen, Pfizer, Takeda, and UCB Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study received institutional board review approval (#IRB21-1355) from the University of Chicago.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}